Sector News

Takeda Announces Consolidation of U.S. Vaccine Sites in Boston/Cambridge Area

June 3, 2015
Life sciences
(BUSINESS WIRE) – Takeda Pharmaceutical Company Limited (“Takeda”) will consolidate its Vaccine Business Unit (VBU) operations by establishing global and regional hubs as the organization continues to grow and advance its important vaccine programs in norovirus, dengue and seasonal influenza.
 
The Boston/Cambridge, Massachusetts area, and Zurich, Switzerland will serve as VBU’s global hubs for the vaccine business outside of Japan. VBU will maintain regional hubs in Singapore and in Brazil and will operate manufacturing sites in Hikari, Japan; Durham, North Carolina and Singen, Germany.
 
In the U.S., all vaccine activities with the exception of manufacturing will move to the new global hub in the Boston/Cambridge area. This co-location will significantly enhance communication and collaboration across VBU’s divisions, and will allow VBU to leverage Takeda’s significant R&D presence in Cambridge. It will also provide access to the area’s remarkable biotech/pharmaceutical ecosystem and talent base.
 
Takeda will close its vaccine site in Bozeman, Montana, which it obtained through the acquisition of Ligocyte Pharmaceuticals in 2012, as well as the Madison, Wisconsin and Fort Collins, Colorado sites, which came to Takeda through the acquisition of Inviragen, Inc. in 2013. In addition, vaccine activities in Deerfield, Illinois, which currently serves as the global headquarters for VBU, will shift to the Boston/Cambridge area. This transition will occur in phases over the next two years, with the completion of U.S. consolidation by mid-2017.
 
“Takeda remains fully committed to the development of innovative vaccines that improve the lives of people around the world, including our norovirus, dengue and seasonal influenza candidate vaccines,” said Rajeev Venkayya, M.D., President, Takeda’s Vaccine Business Unit. “Our sites in Bozeman, Fort Collins, Madison and Deerfield have been instrumental in bringing our dengue and norovirus programs to late stages of clinical development. This consolidation will help us to achieve the efficiency and operational excellence needed to execute the Phase 3 clinical programs and set the stage for global commercialization of these vaccines.”
 
Source: Takeda Pharmaceutical Company Limited

comments closed

Related News

November 26, 2023

ViCentra links insulin pump with Dexcom, Diabeloop tech to launch closed-loop diabetes system in Europe

Life sciences

Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.

November 26, 2023

Boehringer builds out cancer capabilities with $500M deal for bacteria-focused Swiss biotech

Life sciences

Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.

November 26, 2023

EuroAPI completes acquisition of BianoGMP

Life sciences

EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.

How can we help you?

We're easy to reach